Accreditation No: LAB 215

Awarded to

Magns Pharmaceuticals QC Laboratory
Plot ≠ 7B Value Addition City Sahianwala Road Khurrianwala, Faisalabad, Pakistan.

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc and shall not mislead its users.

The accreditation was first time granted on **18-02-2025** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of **ISO/IEC 17025:2017.**

The accreditation requires regular surveillance, and is valid until **17-02-2028.**

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

PAKISTAN NATIONAL ACCREDITATION COUNCIL

18-02-2025
Date

SD
Director General

Testing Laboratory.

Accreditation Scope of Magns Pharmaceuticals QC Laboratory
Plot # 7B Value Addition City Sahianwala Road Khurrianwala
Faisalabad, Pakistan

Permanent laboratory premises X

Sr.#	Materials/Products tested*	Types of test/ Properties measured	Range of measurement	Uncertainty of Measurement (where applicable) (±)	Standard specification/ Techniques/ equipment used
01	Cflox 500 mg Tablet (Ciprofloxacin as HCl)	Assay	90.0 – 110.0%	± 1.0% (Maximum)	HPLC (USP)
02	Cflox 500 mg Tablet (Ciprofloxacin as HCl)	Dissolution Test	NLT 80.0% (Q)		UV/Dissolution Apparatus 2 (USP)
03	Cflox 500 mg Tablet (Ciprofloxacin as HCl)	Disintegration Test (Film Coated)	NMT 30 minutes		Disintegration Apparatus (USP)
04	Cflox 500 mg Tablet (Ciprofloxacin as HCl)	Friability (Uncoated Tablet)	NMT 1.0%		Friability Apparatus (USP)
05	Cflox 500 mg Tablet (Ciprofloxacin as HCl)	Average Weight /Weight Variation	773 mg ± 5.0%		Analytical Weighing Balance (USP)
06	Cflox 500 mg Tablet (Ciprofloxacin as HCl)	Average Thickness (Coated Tablet)	5.43 mm ± 0.5 mm		Vernier Calliper (In House)

18-02-2025
Date

Sd
Director

Sr.#	Materials/Products tested*	Types of test/ Properties measured	Range of measurement	Uncertainty of Measurement (where applicable) (±)	Standard specification/ Techniques/ equipment used
01	Cflox 250 mg Tablet (Ciprofloxacin as HCl)	Assay	90.0 – 110.0%	± 1.0% (Maximum)	HPLC (USP 2019) Volume I Page # 1042
02	Cflox 250 mg Tablet (Ciprofloxacin as HCl)	Dissolution Test	NLT 80.0% (Q)		UV/Dissolution Apparatus 2 (USP 2019) Volume I Page # 1042
03	Cflox 250 mg Tablet (Ciprofloxacin as HCl)	Disintegration Test (Film Coated)	NMT 30 minutes		Disintegration Apparatus (USP 2019) Volume I Page # 1042
04	Cflox 250 mg Tablet (Ciprofloxacin as HCl)	Friability (Uncoated Tablet)	NMT 1.0%		Friability Apparatus (USP)
05	Cflox 250 mg Tablet (Ciprofloxacin as HCl)	Average Weight /Weight Variation	412 mg ± 5.0%		Analytical Weighing Balance (USP 2019) Volume I Page # 1042
06	Cflox 250 mg Tablet (Ciprofloxacin as HCl)	Average Thickness (Coated Tablet)	3.87 mm ± 0.5 mm		Vernier Calliper (In House)

18-02-2025
Date

Sd
Director

Sr.#	Materials/Products tested*	Types of test/ Properties measured	Range of measurement	Uncertainty of Measurement (where applicable) (±)	Standard specification/ Techniques/ equipment used
01	Leufex 500 mg Tablet (Levofloxacin as Hemihydrate)	Assay	90.0 – 110.0%	± 1.0% (Maximum)	HPLC (USP)
02	Leufex 500 mg Tablet (Levofloxacin as Hemihydrate)	Dissolution Test	NLT 80.0% (Q)		UV/Dissolution Apparatus 2 (USP)
03	Leufex 500 mg Tablet (Levofloxacin as Hemihydrate)	Disintegration Test (Film Coated)	NMT 30 minutes		Disintegration Apparatus (USP)
04	Leufex 500 mg Tablet (Levofloxacin as Hemihydrate)	Friability (Uncoated Tablet)	NMT 1.0%		Friability Apparatus (USP)
05	Leufex 500 mg Tablet (Levofloxacin as Hemihydrate)	Average Weight /Weight Variation	773 mg ± 5.0%		Analytical Weighing Balance (USP)
06	Leufex 500 mg Tablet (Levofloxacin as Hemihydrate)	Average Thickness (Coated Tablet)	5.30 mm ± 0.5 mm		Vernier Calliper (In House)

18-02-2025
Date

Sd
Director

Sr.#	Materials/Products tested*	Types of test/ Properties measured	Range of measurement	Uncertainty of Measurement (where applicable) (±)	Standard specification/ Techniques/ equipment used
01	Leufex 250 mg Tablet (Levofloxacin as Hemihydrate)	Assay	90.0 – 110.0%	± 1.0% (Maximum)	HPLC (USP)
02	Leufex 250 mg Tablet (Levofloxacin as Hemihydrate)	Dissolution Test	NLT 80.0% (Q)		UV/Dissolution Apparatus 2 (USP)
03	Leufex 250 mg Tablet (Levofloxacin as Hemihydrate)	Disintegration Test (Film Coated)	NMT 30 minutes		Disintegration Apparatus (USP)
04	Leufex 250 mg Tablet (Levofloxacin as Hemihydrate)	Friability (Uncoated Tablet)	NMT 1.0%		Friability Apparatus (USP)
05	Leufex 250 mg Tablet (Levofloxacin as Hemihydrate)	Average Weight /Weight Variation	412 mg ± 5.0%		Analytical Weighing Balance (USP)
06	Leufex 250 mg Tablet (Levofloxacin as Hemihydrate)	Average Thickness (Coated Tablet)	3.78 mm ± 0.5 mm		Vernier Calliper (In House)

18-02-2025
Date

Sd
Director

Sr.#	Materials/Products tested*	Types of test/ Properties measured	Range of measurement	Uncertainty of Measurement (where applicable) (±)	Standard specification/ Techniques/ equipment used
01	Veloft 50 mg (Delayed Release Tablet) Diclofenac Sodium	Assay	90.0 – 110.0%	± 1.0% (Maximum)	HPLC (USP)
02	Veloft 50 mg (Delayed Release Tablet) Diclofenac Sodium	Dissolution Test (Phosphate Buffer pH 6.8)	NLT 75.0% (Q) After 45 minutes		UV/Dissolution Apparatus 2 (USP)
03	Veloft 50 mg (Delayed Release Tablet) Diclofenac Sodium	Disintegration Test (Enteric Coated) In 0.1 N HCl	No cracking, disintegration or softening after 60 minutes		Disintegration Apparatus (USP)
04	Veloft 50 mg (Delayed Release Tablet) Diclofenac Sodium	Disintegration Test (Enteric Coated) In Phosphate buffer pH 6.8	NMT 45 minutes		Disintegration Apparatus (USP)
05	Veloft 50 mg (Delayed Release Tablet) Diclofenac Sodium	Friability (Uncoated Tablet)	NMT 1.0%		Friability Apparatus (USP)
06	Veloft 50 mg (Delayed Release Tablet) Diclofenac Sodium	Average Weight /Weight Variation	190 mg ± 7.5%		Analytical Weighing Balance (USP)
07	Veloft 50 mg (Delayed Release Tablet) Diclofenac Sodium	Average Thickness (Coated Tablet)	3.40 mm ± 0.5 mm		Vernier Calliper (In House)
08	Veloft 50 mg (Delayed Release Tablet) Diclofenac Sodium	Average Diameter (Coated Tablet)	8.18 mm ± 0.5 mm		Vernier Calliper (In House)

18-02-2025
Date

Sd
Director

Sr.#	Materials/Products tested*	Types of test/ Properties measured	Range of measurement	Uncertainty of Measurement (where applicable) (±)	Standard specification/ Techniques/ equipment used
01	Czet 10 mg Tablet (Cetirizine 2HCl)	Assay	95.0 – 105.0%	± 1.0% (Maximum)	HPLC (BP)
02	Czet 10 mg Tablet (Cetirizine 2HCl)	Dissolution Test	NLT 80.0% (Q)		UV/Dissolution Apparatus 2 (BP)
03	Czet 10 mg Tablet (Cetirizine 2HCl)	Disintegration Test (Film Coated)	NMT 30 minutes		Disintegration Apparatus (BP)
04	Czet 10 mg Tablet (Cetirizine 2HCl)	Friability (Uncoated Tablet)	NMT 1.0%		Friability Apparatus (BP)
05	Czet 10 mg Tablet (Cetirizine 2HCl)	Average Weight /Weight Variation	180 mg ± 7.5%		Analytical Weighing Balance (BP)
06	Czet 10 mg Tablet (Cetirizine 2HCl)	Average Thickness (Coated Tablet)	3.57 mm ± 0.5 mm		Vernier Calliper (In House)
07	Czet 10 mg Tablet (Cetirizine 2HCl)	Average Diameter (Coated Tablet)	8.18 mm ± 0.5 mm		Vernier Calliper (In House)

18-02-2025
Date

Sd
Director

Sr.#	Materials/Products tested*	Types of test/ Properties measured	Range of measurement	Uncertainty of Measurement (where applicable) (±)	Standard specification/ Techniques/ equipment used
01	Veloft 100 mg (Extended Release Tablet) Diclofenac Sodium	Assay	90.0 – 110.0%	± 1.0% (Maximum)	HPLC (USP)
02	Veloft 100 mg (Extended Release Tablet) Diclofenac Sodium	Dissolution Test (0.05 M Phosphate buffer pH 7.5)	USP 41 Monograph (Table 3) Vol. 2 Page # 1259		UV/Dissolution Apparatus 2 (USP)
03	Veloft 100 mg (Extended Release Tablet) Diclofenac Sodium	Friability (Uncoated Tablet)	NMT 1.0%		Friability Apparatus (USP)
04	Veloft 100 mg (Extended Release Tablet) Diclofenac Sodium	Average Weight /Weight Variation	247 mg ± 5.0%		Analytical Weighing Balance (USP)
05	Veloft 100 mg (Extended Release Tablet) Diclofenac Sodium	Average Thickness (Coated Tablet)	3.60 mm ± 0.5 mm		Vernier Calliper (In House)
06	Veloft 100 mg (Extended Release Tablet) Diclofenac Sodium	Average Diameter (Coated Tablet)	8.92 mm ± 0.5 mm		Vernier Calliper (In House)

18-02-2025
Date

Sd
Director

Sr.#	Materials/Products tested*	Types of test/ Properties measured	Range of measurement	Uncertainty of Measurement (where applicable) (±)	Standard specification/ Techniques/ equipment used
01	Veloft 100 mg (Prolong Release Capsule) Diclofenac Sodium	Assay	95.0 – 105.0%	± 1.0% (Maximum)	UV Spectrophotometer (BP)
02	Veloft 100 mg (Extended Release Tablet) Diclofenac Sodium	Average Weight /Weight Variation	390 mg ± 7.5%		Analytical Weighing Balance (BP)

18-02-2025
Date

Sd
Director